GRAIL, Inc.
GRALGRAIL is a commercial-stage healthcare company that develops and commercializes multi-cancer early detection (MCED) technology.
Earnings
Next report
Nov 11, 2026 (in 2 months)Valuation & ratios
Segments
Competitors
By market cap
By revenue growth
By net margin
Profile
GRAIL is a commercial-stage healthcare company that develops and commercializes multi-cancer early detection (MCED) technology. The company's core value proposition is the Galleri test, a blood-based screening tool that identifies a shared cancer signal across more than 50 types of cancer and predicts the tissue of origin. By leveraging a proprietary targeted methylation platform and machine learning, the company aims to shift the paradigm toward early cancer detection at a population scale.
GRAIL is a pioneer and commercial leader in the MCED market with the largest clinical program in genomic medicine to date. It maintains a first-mover advantage with significant real-world data and established partnerships across multiple commercial channels.
FAQ
- What is GRAIL, Inc.'s market cap?
- GRAIL, Inc. (GRAL) has a market capitalization of $3.4B and trades on XNAS.
- What is GRAIL, Inc.'s revenue and profitability?
- GRAIL, Inc. generated $165.3M in trailing twelve-month revenue with a net loss of $391.6M, representing a net margin of -236.9%, with free cash flow of -$296.2M. The latest reported period is Q2 2026.
- Who are GRAIL, Inc.'s competitors?
- GRAIL, Inc.'s key competitors include Guardant Health, Inc., Abbott Laboratories, Natera, Inc., and others. These companies compete in similar markets and product categories.
- Who does GRAIL, Inc. partner with?
- GRAIL, Inc.'s notable partners include Illumina, Inc., Quest Diagnostics, Epic Systems, and others.
- Where is GRAIL, Inc. headquartered?
- GRAIL, Inc. is headquartered in United States of America and employs approximately 1,170 people. It has been publicly traded since 2024.
